Please assess the completion status of the following clinical trial:

Trial Title: Observational Plan to Obtain Clinical Experience and Follow up Data on the Use of the ProxiFuse Hammer Toe Device

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Greater than 18 years of age~* Has a hammertoe deformity causing daily pain and is a surgical candidate for hammertoe procedure in the 2nd, 3rd and/or 4th toe that has failed non-operative measures~* Capable of completing self-administered questionnaires~* Be willing and able to return for all study-related follow up procedures~* Has not participated in any other research protocol within the last 30 days and will not participate in any other research protocol during this study~* If female, is either using contraception or is postmenopausal, or male partner is using contraception~* Has been informed of the nature of the study, agreeing to its requirements, and have signed the informed consent approved by the IRB~Exclusion Criteria:~* Active bacterial infection of the foot/feet to be treated~* Previous hammertoe correction that requires a revision to a toe to be treated under this study~* Patient is on chronic anticoagulation due to a bleeding disorder or has taken anticoagulants within 10 days prior to surgery~* Muscular imbalance, peripheral vascular disease that prohibits adequate healing, or a poor soft tissue envelope in the surgical field, absence of musculoligamentous supporting structures, or peripheral neuropathy~* Patient is not ambulatory or requires an additional surgical procedure that would prohibit the patient from following standard ProxiFuse post-operative recovery procedures~* Additional foot and ankle surgical procedures required during the index procedure other than foot procedures, lapidus and gastrocnemius recession~* Suspected or known allergic reaction to Nickel or Titanium metals~* Co-morbidity that reduces life expectancy to less than 12 months; or~* Patient is a prisoner or ward of the state

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).